JP2023521059A5 - - Google Patents
Info
- Publication number
- JP2023521059A5 JP2023521059A5 JP2022560457A JP2022560457A JP2023521059A5 JP 2023521059 A5 JP2023521059 A5 JP 2023521059A5 JP 2022560457 A JP2022560457 A JP 2022560457A JP 2022560457 A JP2022560457 A JP 2022560457A JP 2023521059 A5 JP2023521059 A5 JP 2023521059A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- hyaluronidase
- minutes
- delivery system
- eye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026002581A JP2026065067A (ja) | 2020-04-02 | 2026-01-09 | ヒアルロニダーゼの投与による目の損傷の低減又は抑制 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063004444P | 2020-04-02 | 2020-04-02 | |
| US63/004,444 | 2020-04-02 | ||
| PCT/US2021/025668 WO2021203062A1 (en) | 2020-04-02 | 2021-04-02 | Reducing or inhibiting ocular damage by hyaluronidase administration |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026002581A Division JP2026065067A (ja) | 2020-04-02 | 2026-01-09 | ヒアルロニダーゼの投与による目の損傷の低減又は抑制 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023521059A JP2023521059A (ja) | 2023-05-23 |
| JP2023521059A5 true JP2023521059A5 (cg-RX-API-DMAC7.html) | 2024-04-10 |
Family
ID=77921064
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022560457A Pending JP2023521059A (ja) | 2020-04-02 | 2021-04-02 | ヒアルロニダーゼの投与による目の損傷の低減又は抑制 |
| JP2026002581A Pending JP2026065067A (ja) | 2020-04-02 | 2026-01-09 | ヒアルロニダーゼの投与による目の損傷の低減又は抑制 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026002581A Pending JP2026065067A (ja) | 2020-04-02 | 2026-01-09 | ヒアルロニダーゼの投与による目の損傷の低減又は抑制 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11878051B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4125928A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023521059A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230005198A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115697348A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021248653B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3174498A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL296979A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022012426A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021203062A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202211833B (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2024003755A (es) * | 2021-09-25 | 2024-04-15 | Med Progress Llc | Reduccion o inhibicion del da?o tisular mediante la administracion de hialuronidasa. |
| KR102922198B1 (ko) * | 2022-04-25 | 2026-02-03 | 주식회사 메디팹 | 조직 수복용 생체재료의 분해 또는 교정용 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8504025D0 (en) | 1985-02-16 | 1985-03-20 | Biopharm Ltd | Hyaluronidase |
| KR100566451B1 (ko) * | 1997-05-22 | 2006-03-31 | 이스타 파마슈티칼스, 인크. | 안질환 치료에서 초자체액의 액화를 위한 안과용 제제의 제조에 있어서의 히알루로니다제의 용도 |
| US20050244472A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intraocular drug delivery systems containing excipients with reduced toxicity and related methods |
| US8197435B2 (en) | 2006-05-02 | 2012-06-12 | Emory University | Methods and devices for drug delivery to ocular tissue using microneedle |
| US20090311237A1 (en) * | 2008-04-14 | 2009-12-17 | Frost Gregory I | Combination therapy using a soluble hyaluronidase and a bisphosphonate |
| US20120101033A1 (en) | 2010-10-05 | 2012-04-26 | Shantha Totada R | Retinitis pigmentosa treatment |
| US11076992B2 (en) | 2019-04-19 | 2021-08-03 | Elt Sight, Inc. | Methods of transverse placement in ELT |
-
2021
- 2021-04-02 IL IL296979A patent/IL296979A/en unknown
- 2021-04-02 JP JP2022560457A patent/JP2023521059A/ja active Pending
- 2021-04-02 WO PCT/US2021/025668 patent/WO2021203062A1/en not_active Ceased
- 2021-04-02 CN CN202180040265.2A patent/CN115697348A/zh active Pending
- 2021-04-02 AU AU2021248653A patent/AU2021248653B2/en active Active
- 2021-04-02 MX MX2022012426A patent/MX2022012426A/es unknown
- 2021-04-02 CA CA3174498A patent/CA3174498A1/en active Pending
- 2021-04-02 KR KR1020227038208A patent/KR20230005198A/ko active Pending
- 2021-04-02 EP EP21782409.3A patent/EP4125928A4/en active Pending
- 2021-04-02 US US17/221,750 patent/US11878051B2/en active Active
-
2022
- 2022-10-31 ZA ZA2022/11833A patent/ZA202211833B/en unknown
-
2026
- 2026-01-09 JP JP2026002581A patent/JP2026065067A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11911379B2 (en) | Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization | |
| TWI874894B (zh) | 含阿托平之水性組成物 | |
| JP7120018B2 (ja) | 眼科用製品及び粘度低下抑制方法 | |
| JP7716115B2 (ja) | 薬剤送達用生体溶解性医薬ゲル | |
| WO2020062445A1 (zh) | 防治nitm的药物组合物及其医药用途 | |
| WO2021116679A1 (en) | Treatments of diabetic macular edema and impaired visual acuity | |
| Aptel et al. | Noninferiority of preservative-free versus BAK-preserved latanoprost-timolol fixed combination eye drops in patients with open-angle glaucoma or ocular hypertension | |
| JP2022062153A (ja) | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 | |
| CN109010803A (zh) | 一种重组人干扰素α2b滴眼液及其制备方法 | |
| KR102314706B1 (ko) | 안압 강하용 점안 조성물 | |
| ES2943933T3 (es) | Colirios de palonosetrón para el tratamiento o la prevención de náuseas y vómitos | |
| US20250017902A1 (en) | Pharmaceutical composition for treating migraine | |
| KR20230005198A (ko) | 히알루로니다제 투여에 의한 안구 손상 감소 또는 억제 | |
| Ober et al. | Measurement of the actual dose of triamcinolone acetonide delivered by common techniques of intravitreal injection | |
| Borkenstein et al. | Calculated drug concentrations in currently available intravitreal therapies: determination of dilution factor and deviation from recommended doses | |
| Soares et al. | Efficacy of the combination of carteolol hydrochloride+ latanoprost in the treatment of glaucoma and ocular hypertension | |
| Borkar et al. | Sustained release corticosteroid therapy for noninfectious uveitis | |
| CN115025115A (zh) | 一种复方尿维氨滴眼液 | |
| Witika et al. | Clinical applications of long acting injectables: Systemic and local drug delivery | |
| HU207455B (en) | Method for producing pharmaceutical preparations suitable for treating postischemical heart-troubles containing captoprile and in given case thrombolitic agent | |
| Thomas et al. | Study of the additive effect of timolol and epinephrine in lowering intraocular pressure. | |
| CN104703606B (zh) | 1-金刚烷乙氧基-3-吗啉基-2-丙醇或其药学上可接受的盐在药物组合物中作为视神经网膜保护物使用 | |
| Lee et al. | Macular Infarction Following Intravitreal Triamcinolone Injection for Treatment of Central Retinal Vein Occlusion | |
| BG1841U1 (bg) | Парентерална лекарствена форма | |
| Novack | New horizons in glaucoma drug delivery |